Alan S. Wayne, MD

Chair, Department of Pediatrics

Professor of Pediatrics, Medicine, and Cancer Biology, Keck School of Medicine of USC

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair Children's Hospital Los Angeles

Image of Alan S. Wayne, MD
Is this your profile? Click to edit

Overview

Alan S. Wayne, MD serves as Chair of the Department of Pediatrics at the Keck School of Medicine of USC and Senior Vice President of Academic Affairs and Pediatrician-in-Chief at Children’s Hospital Los Angeles (CHLA). Dr. Wayne is Professor of Pediatrics and Medicine at the Keck School of Medicine of USC. In these roles, Dr. Wayne oversees the Department’s clinical care delivery, medical education, and research programs, and leads the departmental strategy, faculty affairs, and budget management in the context of the missions of USC and CHLA.

Dr. Wayne’s primary research efforts are directed toward the development of new treatment approaches for leukemias and lymphomas, with a focus on targeted, immune-based, and cellular therapies. He is the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group headquartered at CHLA. He has an ongoing leadership role in the development of genetically modified chimeric antigen receptor (CAR) T-cells for childhood hematologic malignancies. Additionally, he plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies, the primary aim of which is to study the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation.

Board-certified in pediatric hematology-oncology, Dr. Wayne attended the Honors Program in Medical Education obtaining his BS and MD degrees from Northwestern University. He conducted internship, residency, and chief residency in pediatrics at Boston Children’s Hospital followed by pediatric hematology-oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Research Funding

  • Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
    NIH · U01AI126612 · Aug 24, 2017 – Jul 31, 2024 · Role: Principal Investigator
  • University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
    NIH · P30CA014089 · Apr 1, 1980 – Nov 30, 2026 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · Z01BC010596 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · Z01BC010764 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · Z01SC010353 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · ZICBC010596 · Role: Principal Investigator
  • Behavioral Science Core
    NIH · ZICBC011288 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · ZICSC010353 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · ZIEBC010764 · Role: Principal Investigator

Publications

  • The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. Cancers (Basel). 2017 Sep 10; 9(9).. View in PubMed
  • Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 10 05; 130(14):1620-1627.. View in PubMed
  • Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017; 6(1):1294368.. View in PubMed
  • Induction of Immune Response after Allogeneic Wilms’ Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. Biol Blood Marrow Transplant. 2016 12; 22(12):2149-2154.. View in PubMed
  • Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016 11; 63(11):1943-8.. View in PubMed
  • Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. J Pediatr Hematol Oncol. 2016 07; 38(5):345-9.. View in PubMed
  • Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. Clin Cancer Res. 2016 Oct 01; 22(19):4913-4922.. View in PubMed
  • Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins. Mol Cancer Ther. 2016 05; 15(5):1053-62.. View in PubMed
  • Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. Pediatr Blood Cancer. 2016 Jun; 63(6):997-1005.. View in PubMed
  • Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. Invest New Drugs. 2016 Feb; 34(1):61-5.. View in PubMed